(Q42546905)

2 November 2017

title

A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia (English)

1 reference

2 November 2017

0 references

1 reference

Peuskens J

1

1 reference

2 November 2017

Link CG

series ordinal

2

1 reference

2 November 2017

language of work or name

English

0 references

publication date

1 October 1997

1 reference

Acta Psychiatrica Scandinavica

2 November 2017

published in

1 reference

2 November 2017

volume

96

1 reference

2 November 2017

issue

4

1 reference

2 November 2017

page(s)

265-273

1 reference

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

2 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1997.TB10162.X

Agranulocytosis during treatment with chlozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1997.TB10162.X

Seroquel: biochemical profile of a potential atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1997.TB10162.X

Clozapine increases rat serum prolactin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1997.TB10162.X

Differential Effects of Classical and Atypical Antipsychotic Drugs on A9 and A10 Dopamine Neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1997.TB10162.X

Seroquel: electrophysiological profile of a potential atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1997.TB10162.X

Clozapine: neuroleptic-induced EPS and tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1997.TB10162.X

Seroquel: behavioral effects in conventional and novel tests for atypical antipsychotic drug.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1997.TB10162.X

ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1997.TB10162.X

Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1997.TB10162.X

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1997.TB10162.X

10.1111/J.1600-0447.1997.TB10162.X

21 January 2018

Identifiers

DOI

1 reference

2 November 2017

1 reference